Published in Brain on December 01, 1993
The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet (1997) 1.35
Marked phenotypic heterogeneity associated with expansion of a CAG repeat sequence at the spinocerebellar ataxia 3/Machado-Joseph disease locus. Am J Hum Genet (1995) 1.15
The gene for autosomal dominant cerebellar ataxia type II is located in a 5-cM region in 3p12-p13: genetic and physical mapping of the SCA7 locus. Am J Hum Genet (1996) 1.06
The gene for spinal cerebellar ataxia 3 (SCA3) is located in a region of approximately 3 cM on chromosome 14q24.3-q32.2. Am J Hum Genet (1995) 0.94
Swallowing in degenerative ataxias. J Neurol (2006) 0.89
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (1996) 11.59
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet (2000) 5.05
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet (1999) 4.74
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Genome-wide scan for autism susceptibility genes. Paris Autism Research International Sibpair Study. Hum Mol Genet (1999) 3.93
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat Genet (2001) 3.15
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet (1999) 3.14
Predominant dystonia with marked cerebellar atrophy: a rare phenotype in familial dystonia. Neurology (2006) 3.07
Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature (1995) 2.92
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev Cell (2001) 2.73
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry (1998) 2.55
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology (2009) 2.46
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet (1996) 2.40
Parental consanguinity as a cause of increased incidence of birth defects in a study of 131,760 consecutive births. Am J Med Genet (1994) 2.40
Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet (2000) 2.40
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat Genet (1996) 2.29
The mental representation of hand movements after parietal cortex damage. Science (1996) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg (2000) 2.25
Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int (2000) 2.20
Frequency of the DYT1 mutation in primary torsion dystonia without family history. Arch Neurol (2000) 2.17
Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology (2012) 2.12
The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain (1998) 2.11
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol (1998) 2.04
Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat Genet (1993) 2.03
Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol (1999) 2.02
The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain (1999) 2.00
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A (2000) 1.97
X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology (1998) 1.96
Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet (2003) 1.96
Unidirectional replication in Escherichia coli of three small plasmids derived from R factor R12. Plasmid (1977) 1.91
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem (1992) 1.91
Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain (2009) 1.91
DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci (2003) 1.90
A novel DCC mutation and genetic heterogeneity in congenital mirror movements. Neurology (2011) 1.88
Autism, language delay and mental retardation in a patient with 7q11 duplication. J Med Genet (2007) 1.86
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology (2000) 1.85
Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1994) 1.85
Parkinson's disease and sleepiness: an integral part of PD. Neurology (2002) 1.85
Eye movements in parkinsonian syndromes. Ann Neurol (1994) 1.84
Cortical control of reflexive visually-guided saccades. Brain (1991) 1.84
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol (2008) 1.82
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. Eur Heart J (1998) 1.79
Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol (1996) 1.77
A third locus for autosomal dominant cerebellar ataxia type I maps to chromosome 14q24.3-qter: evidence for the existence of a fourth locus. Am J Hum Genet (1994) 1.76
Genome screen for asthma and related phenotypes in the French EGEA study. Am J Respir Crit Care Med (2000) 1.75
A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology (2008) 1.74
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology (1987) 1.70
Pallidal stimulation for Parkinson's disease. Two targets? Neurology (1997) 1.69
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res (1983) 1.67